NT219 is a potent and dual inhibitor of insulin receptor substrates 1/2 ( IRS1/2 ) and STAT3. IRS1/2 and STAT3 are major signaling junctions regulated by various oncogenes. NT219 affects IRS1/2 degradation and inhibits STAT3 phosphorylation. NT219 has the potential for the research of cancer diseases.